{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:44:54Z","timestamp":1761155094007,"version":"3.40.5"},"reference-count":95,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:p>Adolescents in the United States now have the opportunity to receive new vaccines that prevent invasive meningococcal infections, pertussis (whooping cough), and cervical cancer. Except for their potential to cause serious illness, these infections could not be more different. Their incidence ranges from extremely low to quite high. Early clinical manifestations of infection range from none to life-threatening illness. Two of the vaccines are similar to those already in use, whereas 1 is completely new. In conjunction with the 4 vaccines previously recommended for adolescents (the tetanus and diphtheria booster, hepatitis B, measles-mumps-rubella, and varicella), the 3 new vaccines (meningococcal, human papillomavirus, and the tetanus-diphtheria-pertussis booster [which replaced the tetanus-diphtheria booster]) bring the number recommended for adolescents to 6. In this article, we describe key characteristics of the 3 new vaccines and infections they were designed to prevent. We also briefly discuss other vaccines recommended for all adolescents who have not already received them and new vaccines that are still under development.<\/jats:p>","DOI":"10.1542\/peds.2007-1115b","type":"journal-article","created":{"date-parts":[[2008,1,3]],"date-time":"2008-01-03T16:53:24Z","timestamp":1199379204000},"page":"S5-S14","source":"Crossref","is-referenced-by-count":12,"title":["New, and Some Not-so-New, Vaccines for Adolescents and Diseases They Prevent"],"prefix":"10.1542","volume":"121","author":[{"given":"Daniel B.","family":"Fishbein","sequence":"first","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen R.","family":"Broder","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauri","family":"Markowitz","sequence":"additional","affiliation":[{"name":"National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Messonnier","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2008,1,1]]},"reference":[{"key":"2021120823300224900_R1","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. Pediatrics.\u20081997;99:479\u2013488","DOI":"10.1542\/peds.99.3.479"},{"key":"2021120823300224900_R2","unstructured":"Centers for Disease Control and Prevention. Measles prevention. MMWR Morb Mortal Wkly Rep.\u20081989;38(suppl 9):1\u201318"},{"key":"2021120823300224900_R3","unstructured":"Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep.\u20081996;45:1\u201336"},{"key":"2021120823300224900_R4","unstructured":"Centers for Disease Control and Prevention. Update: recommendations to prevent hepatitis B virus transmission\u2014United States. MMWR Morb Mortal Wkly Rep.\u20081995;44:574\u2013575"},{"key":"2021120823300224900_R5","unstructured":"Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20082005;54(RR-7):1\u201321"},{"key":"2021120823300224900_R6","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics.\u20082005;116:496\u2013505","DOI":"10.1542\/peds.2005-1314"},{"key":"2021120823300224900_R7","doi-asserted-by":"crossref","unstructured":"Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20082006;55(RR-3):1\u201334","DOI":"10.1037\/e506922006-001"},{"key":"2021120823300224900_R8","doi-asserted-by":"crossref","unstructured":"Markowitz L, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20082007;56(RR-2):1\u201324","DOI":"10.1037\/e601292007-001"},{"key":"2021120823300224900_R9","doi-asserted-by":"crossref","unstructured":"Raghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. Annu Rev Med.\u20082004;55:333\u2013353","DOI":"10.1146\/annurev.med.55.091902.103612"},{"key":"2021120823300224900_R10","doi-asserted-by":"crossref","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med.\u20082001;344:1378\u20131388","DOI":"10.1056\/NEJM200105033441807"},{"key":"2021120823300224900_R11","doi-asserted-by":"crossref","unstructured":"Brooks R, Woods CW, Benjamin DK Jr, Rosenstein NE. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994\u20132002. Clin Infect Dis.\u20082006;43:49\u201354","DOI":"10.1086\/504804"},{"key":"2021120823300224900_R12","doi-asserted-by":"crossref","unstructured":"Kelly DF, Pollard AJ, Moxon ER. Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA.\u20082005;294:3019\u20133023","DOI":"10.1001\/jama.294.23.3019"},{"key":"2021120823300224900_R13","doi-asserted-by":"crossref","unstructured":"Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis.\u20082006;193:821\u2013828","DOI":"10.1086\/500512"},{"key":"2021120823300224900_R14","unstructured":"Centers for Disease Control and Prevention. Notice to readers: limited supply of meningococcal conjugate vaccine, recommendations to defer vaccination of persons age 11\u201312 years. MMWR Morb Mortal Wkly Rep.\u20082006;55:567\u2013568"},{"key":"2021120823300224900_R15","unstructured":"Campos-Outcalt D. Meningococcal vaccine: new product, new recommendations. J Fam Pract.\u20082005;54:324\u2013326"},{"key":"2021120823300224900_R16","unstructured":"Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11\u201318 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep.\u20082007;56:794\u2013795"},{"key":"2021120823300224900_R17","unstructured":"Lorick S, Fishbein DB, Wortley P, Weintraub E, Kong Y, Lee G. Menactra's uptake patterns among adolescents\u2014United States, 2005. Presented at Prevention 2007, Annual Meeting of the American Academy of Preventive Medicine. Miami, FL: 2007"},{"key":"2021120823300224900_R18","unstructured":"Centers for Disease Control and Prevention. Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine: United States, June-July 2005. MMWR Morb Mortal Wkly Rep.\u20082005;54:1023\u20131025"},{"key":"2021120823300224900_R19","unstructured":"Centers for Disease Control and Prevention. Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine: United States, October 2005-February 2006. MMWR Morb Mortal Wkly Rep.\u20082006;55:364\u2013366"},{"key":"2021120823300224900_R20","doi-asserted-by":"crossref","unstructured":"Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev.\u20082005;18:326\u2013382","DOI":"10.1128\/CMR.18.2.326-382.2005"},{"key":"2021120823300224900_R21","doi-asserted-by":"crossref","unstructured":"Linnemann CC Jr, Bass JW, Smith MH. The carrier state in pertussis. Am J Epidemiol.\u20081968;88:422\u2013427","DOI":"10.1093\/oxfordjournals.aje.a120903"},{"key":"2021120823300224900_R22","doi-asserted-by":"crossref","unstructured":"Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980\u20131999. JAMA.\u20082003;290:2968\u20132975","DOI":"10.1001\/jama.290.22.2968"},{"key":"2021120823300224900_R23","doi-asserted-by":"crossref","unstructured":"Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med.\u20082005;353:1555\u20131563","DOI":"10.1056\/NEJMoa050824"},{"key":"2021120823300224900_R24","doi-asserted-by":"crossref","unstructured":"Hewlett EL, Edwards KM. Clinical practice: pertussis\u2014not just for kids. N Engl J Med.\u20082005;352:1215\u20131222","DOI":"10.1056\/NEJMcp041025"},{"key":"2021120823300224900_R25","doi-asserted-by":"crossref","unstructured":"De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis.\u20082000;182:174\u2013179","DOI":"10.1086\/315648"},{"key":"2021120823300224900_R26","doi-asserted-by":"crossref","unstructured":"Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis.\u20082004;39:1572\u20131580","DOI":"10.1086\/425006"},{"key":"2021120823300224900_R27","doi-asserted-by":"crossref","unstructured":"Sotir MJ, Cappozzo DL, Warshauer DM, et al. Evaluation of polymerase chain reaction and culture for diagnosis of pertussis in the control of a county-wide outbreak focused among adolescents and adults. Clin Infect Dis.\u20082007;44:1216\u20131219","DOI":"10.1086\/513432"},{"key":"2021120823300224900_R28","doi-asserted-by":"crossref","unstructured":"Davis JP. Clinical and economic effects of pertussis outbreaks. Pediatr Infect Dis J.\u20082005;24:S109\u2013S116","DOI":"10.1097\/01.inf.0000166156.14422.9b"},{"key":"2021120823300224900_R29","unstructured":"Bisgard KM, Pascual B, Tiwaria T, Murphy T. Pertussis. In: Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine-Preventable Diseases. 3rd ed. Atlanta, GA: US Department of Health and Human Services; 2002"},{"key":"2021120823300224900_R30","unstructured":"Centers for Disease Control and Prevention. Pertussis: United States, 1997\u20132000. MMWR Morb Mortal Wkly Rep.\u20082002;51:73\u201376"},{"key":"2021120823300224900_R31","unstructured":"McNabb SJ, Jajosky RA, Hall-Baker PA, et al. Summary of notifiable diseases 2005. MMWR Recomm Rep.\u20082007;54:1\u201392"},{"key":"2021120823300224900_R32","doi-asserted-by":"crossref","unstructured":"Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J. Defining pertussis epidemiology: clinical, microbiologic, and serologic perspectives. Pediatr Infect Dis J.\u20082005;24(suppl 5):S25\u2013S34","DOI":"10.1097\/01.inf.0000160926.89577.3b"},{"key":"2021120823300224900_R33","doi-asserted-by":"crossref","unstructured":"Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis.\u20082004;39:1802\u20131809","DOI":"10.1086\/426020"},{"key":"2021120823300224900_R34","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: prevention of pertussis among adolescents\u2014recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine. Available at: www.aap.org\/advocacy\/releases\/Tdap121205.pdf. Accessed July 8, 2007"},{"key":"2021120823300224900_R35","doi-asserted-by":"crossref","unstructured":"Halperin SA, Sweet L, Baxendale D, et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?Pediatr Infect Dis J.\u20082006;25:195\u2013200","DOI":"10.1097\/01.inf.0000202082.56403.c4"},{"key":"2021120823300224900_R36","doi-asserted-by":"crossref","unstructured":"Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine.\u20082006;24(suppl 1):S1\u2013S15","DOI":"10.1016\/j.vaccine.2005.09.054"},{"key":"2021120823300224900_R37","doi-asserted-by":"crossref","unstructured":"Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health.\u20082004;36:6\u201310","DOI":"10.1363\/3600604"},{"key":"2021120823300224900_R38","doi-asserted-by":"crossref","unstructured":"Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol.\u20082000;151:1158\u20131171","DOI":"10.1093\/oxfordjournals.aje.a010166"},{"key":"2021120823300224900_R39","doi-asserted-by":"crossref","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P. Global cancers statistics, 2002. CA Cancer J Clin.\u20082005;55:74\u2013108","DOI":"10.3322\/canjclin.55.2.74"},{"key":"2021120823300224900_R40","doi-asserted-by":"crossref","unstructured":"Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16\/18 vaccine. Int J Cancer.\u20082003;106:896\u2013904","DOI":"10.1002\/ijc.11334"},{"key":"2021120823300224900_R41","unstructured":"US Cancer Statistics Working Group. United States Cancer Statistics: 2003\u2014Incidence and Mortality. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, and the National Cancer Institute; 2006"},{"key":"2021120823300224900_R42","doi-asserted-by":"crossref","unstructured":"Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published correction appears in CA Cancer J Clin. 2005;55:259]. CA Cancer J Clin.\u20082005;55:10\u201330","DOI":"10.3322\/canjclin.55.1.10"},{"key":"2021120823300224900_R43","doi-asserted-by":"crossref","unstructured":"Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine.\u20082005;23:2388\u20132394","DOI":"10.1016\/j.vaccine.2005.01.016"},{"key":"2021120823300224900_R44","doi-asserted-by":"crossref","unstructured":"Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med.\u20082002;347:1645\u20131651","DOI":"10.1056\/NEJMoa020586"},{"key":"2021120823300224900_R45","unstructured":"Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol.\u20082005;6:271\u2013278"},{"key":"2021120823300224900_R46","doi-asserted-by":"crossref","unstructured":"Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet.\u20082006;367:1247\u20131255","DOI":"10.1016\/S0140-6736(06)68439-0"},{"key":"2021120823300224900_R47","doi-asserted-by":"crossref","unstructured":"Markowitz LE. HPV vaccines prophylactic, not therapeutic. JAMA.\u20082007;298:805\u2013806","DOI":"10.1001\/jama.298.7.805"},{"key":"2021120823300224900_R48","doi-asserted-by":"crossref","unstructured":"Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA.\u20082007;298:743\u2013753","DOI":"10.1001\/jama.298.7.743"},{"key":"2021120823300224900_R49","doi-asserted-by":"crossref","unstructured":"Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA.\u20081995;274:1201\u20131208","DOI":"10.1001\/jama.274.15.1201"},{"key":"2021120823300224900_R50","unstructured":"Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage among children aged 19\u201335 months: United States, 2004. MMWR Morb Mortal Wkly Rep.\u20082005;54:717\u2013721"},{"key":"2021120823300224900_R51","unstructured":"Centers for Disease Control and Prevention. Acute hepatitis B among children and adolescents: United States, 1990\u20132002. MMWR Morb Mortal Wkly Rep.\u20082004;53:1015\u20131018"},{"key":"2021120823300224900_R52","doi-asserted-by":"crossref","unstructured":"Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982\u20131998: implications for vaccination programs. J Infect Dis.\u20082002;185:713\u2013719","DOI":"10.1086\/339192"},{"key":"2021120823300224900_R53","doi-asserted-by":"crossref","unstructured":"Perz JF, Elm JL Jr, Fiore AE, Huggler JI, Kuhnert WL, Effler PV. Near elimination of hepatitis B virus infections among Hawaii elementary school children after universal infant hepatitis B vaccination. Pediatrics.\u20082006;118:1403\u20131408","DOI":"10.1542\/peds.2006-0724"},{"key":"2021120823300224900_R54","doi-asserted-by":"crossref","unstructured":"Wilson TR, Fishbein DB, Ellis PA, Edlavitch SA. The impact of a school entry law on adolescent immunization rates. J Adolesc Health.\u20082005;37:511\u2013516","DOI":"10.1016\/j.jadohealth.2005.07.009"},{"key":"2021120823300224900_R55","doi-asserted-by":"crossref","unstructured":"Fogarty KJ, Massoudi MS, Gallo W, Averhoff FM, Yusuf H, Fishbein D. Vaccine coverage levels after implementation of a middle school vaccination requirement, Florida, 1997\u20132000. Public Health Rep.\u20082004;119:163\u2013169","DOI":"10.1177\/003335490411900209"},{"key":"2021120823300224900_R56","doi-asserted-by":"crossref","unstructured":"Averhoff F, Linton L, Peddecord KM, Edwards C, Wang W, Fishbein D. A middle school immunization law rapidly and substantially increases immunization coverage among adolescents. Am J Public Health.\u20082004;94:978\u2013984","DOI":"10.2105\/AJPH.94.6.978"},{"key":"2021120823300224900_R57","doi-asserted-by":"crossref","unstructured":"Rickert D, Deladisma A, Yusuf H, Averhoff F, Brink E, Shih S. Adolescent immunizations: are we ready for a new wave?Am J Prev Med.\u20082004;26:22\u201328","DOI":"10.1016\/j.amepre.2003.09.001"},{"key":"2021120823300224900_R58","unstructured":"Centers for Disease Control and Prevention. Recommendation of the Immunization Practices Advisory Committee (ACIP): inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep.\u20081982;31:317\u2013322, 327\u2013328"},{"key":"2021120823300224900_R59","unstructured":"Centers for Disease Control and Prevention. Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. MMWR Morb Mortal Wkly Rep.\u20081988;10(37):341\u2013346, 351"},{"key":"2021120823300224900_R60","unstructured":"Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR Recomm Rep.\u20081991;40(RR-13):1\u201319"},{"key":"2021120823300224900_R61","unstructured":"Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1\u2014immunization of infants, children, and adolescents [published correction appears in MMWR Morb Mortal Weekly Rep. 2006;55:158\u2013159]. MMWR Recomm Rep.\u20082005;54(RR-16):1\u201331"},{"key":"2021120823300224900_R62","unstructured":"Centers for Disease Control and Prevention. Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep.\u20081995;44:1\u201322"},{"key":"2021120823300224900_R63","unstructured":"Centers for Disease Control and Prevention. Update: recommendations to prevent hepatitis B virus transmission\u2014United States. MMWR Morb Mortal Wkly Rep.\u20081999;48:33\u201334"},{"key":"2021120823300224900_R64","doi-asserted-by":"crossref","unstructured":"Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med.\u20082005;352:450\u2013458","DOI":"10.1056\/NEJMoa042271"},{"key":"2021120823300224900_R65","doi-asserted-by":"crossref","unstructured":"Khoshnood B, Debruyne M, Lancon F, et al. Seroprevalence of varicella in the French population. Pediatr Infect Dis J.\u20082006;25:41\u201344","DOI":"10.1097\/01.inf.0000195636.43584.bb"},{"key":"2021120823300224900_R66","doi-asserted-by":"crossref","unstructured":"Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med.\u20082002;347:1909\u20131915","DOI":"10.1056\/NEJMoa021662"},{"key":"2021120823300224900_R67","doi-asserted-by":"crossref","unstructured":"Luman ET, Ching PL, Jumaan AO, Seward JF. Uptake of varicella vaccination among young children in the United States: a success story in eliminating racial and ethnic disparities. Pediatrics.\u20082006;117:999\u20131008","DOI":"10.1542\/peds.2005-1201"},{"key":"2021120823300224900_R68","doi-asserted-by":"crossref","unstructured":"Lopez AS, Lett SM, Yih WK, Northrup J, Jumaan AO, Seward JF. Increasing evidence of immunity to varicella among children in Massachusetts, 1999\u20132003. Am J Prev Med.\u20082006;30:232\u2013236","DOI":"10.1016\/j.amepre.2005.10.022"},{"key":"2021120823300224900_R69","doi-asserted-by":"crossref","unstructured":"Hall S, Maupin T, Seward J, et al. Second varicella infections: are they more common than previously thought?Pediatrics.\u20082002;109:1068\u20131073","DOI":"10.1542\/peds.109.6.1068"},{"key":"2021120823300224900_R70","doi-asserted-by":"crossref","unstructured":"Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000. JAMA.\u20082002;287:606\u2013611","DOI":"10.1001\/jama.287.5.606"},{"key":"2021120823300224900_R71","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics.\u20082007;120:221\u2013231","DOI":"10.1542\/peds.2007-1089"},{"key":"2021120823300224900_R72","doi-asserted-by":"crossref","unstructured":"Richmond JB. Measles elimination: why not now?JAMA.\u20081979;242:1175\u20131176","DOI":"10.1001\/jama.242.11.1175"},{"key":"2021120823300224900_R73","doi-asserted-by":"crossref","unstructured":"Atkinson WL, Orenstein WA, Krugman S. The resurgence of measles in the United States, 1989\u20131990. Annu Rev Med.\u20081992;43:451\u2013463","DOI":"10.1146\/annurev.me.43.020192.002315"},{"key":"2021120823300224900_R74","doi-asserted-by":"crossref","unstructured":"Kolasa MS, Klemperer-Johnson S, Papania MJ. Progress toward implementation of a second-dose measles immunization requirement for all schoolchildren in the United States. J Infect Dis.\u20082004;189(suppl 1):S98\u2013S103","DOI":"10.1086\/374720"},{"key":"2021120823300224900_R75","doi-asserted-by":"crossref","unstructured":"Gindler J, Tinker S, Markowitz L, Atkinson W, Dales L, Papania MJ. Acute measles mortality in the United States, 1987\u20132002. J Infect Dis.\u20082004;189(suppl 1):S69\u2013S77","DOI":"10.1086\/378565"},{"key":"2021120823300224900_R76","unstructured":"Centers for Disease Control and Prevention. Achievements in public health: elimination of rubella and congenital rubella syndrome\u2014United States, 1969\u20132004. MMWR Morb Mortal Wkly Rep.\u20082005;54:279\u2013282"},{"key":"2021120823300224900_R77","doi-asserted-by":"crossref","unstructured":"Yeung LF, Lurie P, Dayan G, et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics.\u20082005;116:1287\u20131291","DOI":"10.1542\/peds.2004-2718"},{"key":"2021120823300224900_R78","unstructured":"Centers for Disease Control and Prevention. Mumps epidemic: Iowa, 2006. MMWR Morb Mortal Wkly Rep.\u20082006;55:366\u2013368"},{"key":"2021120823300224900_R79","doi-asserted-by":"crossref","unstructured":"Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ.\u20082005;330:1132\u20131135","DOI":"10.1136\/bmj.330.7500.1132"},{"key":"2021120823300224900_R80","doi-asserted-by":"crossref","unstructured":"Ada G. Overview of vaccines and vaccination. Mol Biotechnol.\u20082005;29:255\u2013272","DOI":"10.1385\/MB:29:3:255"},{"key":"2021120823300224900_R81","doi-asserted-by":"crossref","unstructured":"Ada G. Vaccines and vaccination. N Engl J Med.\u20082001;345:1042\u20131053","DOI":"10.1056\/NEJMra011223"},{"key":"2021120823300224900_R82","doi-asserted-by":"crossref","unstructured":"Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism?Clin Diagn Lab Immunol.\u20082004;11:437\u2013445","DOI":"10.1128\/CDLI.11.3.437-445.2004"},{"key":"2021120823300224900_R83","doi-asserted-by":"crossref","unstructured":"Jones CA, Knipe D. Herpes simplex virus vaccines. Pediatr Infect Dis J.\u20082003;22:1003\u20131005","DOI":"10.1097\/01.inf.0000095200.04954.fe"},{"key":"2021120823300224900_R84","doi-asserted-by":"crossref","unstructured":"Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis.\u20082004;39:233\u2013239","DOI":"10.1086\/421999"},{"key":"2021120823300224900_R85","unstructured":"Schleiss M. Progress in cytomegalovirus vaccine development. Herpes.\u20082005;12:66\u201375"},{"key":"2021120823300224900_R86","unstructured":"Centers for Disease Control and Prevention. Impact of vaccines universally recommended for children: United States, 1990\u20131998. MMWR Morb Mortal Wkly Rep.\u20081999;48:243\u2013248"},{"key":"2021120823300224900_R87","doi-asserted-by":"crossref","unstructured":"Szilagyi P, Rand CM, McLaurin J, et al. Delivering adolescent vaccinations in the medical home: a new era?Pediatrics.\u20082007;121:S15\u2013S24","DOI":"10.1542\/peds.2007-1115C"},{"key":"2021120823300224900_R88","doi-asserted-by":"crossref","unstructured":"Broder KR, Cohn AC, Schwartz B, et al. Adolescent immunizations and other clinical preventive services: a needle and a hook?Pediatrics.\u20082007;121:S25\u2013S34","DOI":"10.1542\/peds.2007-1115D"},{"key":"2021120823300224900_R89","doi-asserted-by":"crossref","unstructured":"Sneller V-P, Fishbein, DF, Weinbaum CM, et al. Vaccinating adolescents in high-risk settings: lessons learned from experiences with hepatitis B vaccine. Pediatrics.\u20082007;121:S55\u2013S62","DOI":"10.1542\/peds.2007-1115G"},{"key":"2021120823300224900_R90","doi-asserted-by":"crossref","unstructured":"Moyer VA, Butler M. Gaps in the evidence for well-child care: a challenge to our profession. Pediatrics.\u20082004;114:1511\u20131521","DOI":"10.1542\/peds.2004-1076"},{"key":"2021120823300224900_R91","doi-asserted-by":"crossref","unstructured":"Task Force on Community Preventive Services, Zaza S, Briss PA. The Guide to Community Preventive Services: What Works to Promote Health? New York, NY: Oxford University Press; 2005","DOI":"10.1093\/acprof:oso\/9780195151091.001.0001"},{"key":"2021120823300224900_R92","doi-asserted-by":"crossref","unstructured":"Yarnall KS, McBride CM, Lyna P, et al. Factors associated with condom use among at-risk women students and nonstudents seen in managed care. Prev Med.\u20082003;37:163\u2013170","DOI":"10.1016\/S0091-7435(03)00109-9"},{"key":"2021120823300224900_R93","unstructured":"Zwanziger J, Szilagyi PG, Kaul P. Evaluating the benefits of increasing measles immunization rates. Health Serv Res.\u20082001;36:885\u2013909"},{"key":"2021120823300224900_R94","doi-asserted-by":"crossref","unstructured":"Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med.\u20082006;31:52\u201361","DOI":"10.1016\/j.amepre.2006.03.012"},{"key":"2021120823300224900_R95","doi-asserted-by":"crossref","unstructured":"Coffield AB, Maciosek MV, McGinnis JM, et al. Priorities among recommended clinical preventive services. Am J Prev Med.\u20082001;21:1\u20139","DOI":"10.1016\/S0749-3797(01)00308-7"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/Supplement_1\/S5\/1003726\/zpe101080000s5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/Supplement_1\/S5\/1003726\/zpe101080000s5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:22:53Z","timestamp":1684171373000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/Supplement_1\/S5\/70134\/New-and-Some-Not-so-New-Vaccines-for-Adolescents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":95,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2008,1,1]]},"published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-1115b","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}